13 research outputs found
The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysis
Factors associated with rapid progression in fibrotic interstitial lung disease
Background: Early identification of fibrotic interstitial lung disease (F-ILD) patients with high risk of progression will help initiate early therapeutic intervention and potential improvement of outcomes. This study was designed to assess the predictors of progression in patients with F-ILD. Methods: Patients with F-ILD in Shanghai Pulmonary Hospital between January 1, 2019 and July 31, 2021 were retrospectively analyzed. The patients enrolled were divided into progressive group and non-progressive group according to the specified criteria. Baseline characteristics were collected and a multivariate regression was conducted to identify independent predictors of progression. Results: Of the 177Â F-ILD cases, 87 were enrolled in the progressive group and 90 were in the non-progressive group. The cohort included 11 types of F-ILD, primarily were connective tissue disease-associated interstitial lung disease (CTD-ILD) (43, 24.3Â %), idiopathic pulmonary fibrosis (IPF) (39, 22.0Â %), interstitial pneumonia with autoimmune features (IPAF) (32, 18.1Â %), and unclassifiable (23, 13.0Â %). The highest proportion of progression was seen in nonspecific interstitial pneumonia (NSIP) subgroup (66.7Â %), followed by IPF (59.0Â %) and HP (57.1Â %). After adjusting for gender and age, a course of disease longer than 9.5 months (OR: 2.633; 95Â % CI: 1.190â5.826, PÂ =Â 0.017), lymphocyte in peripheral blood more than 2.24 (109/L) (OR: 2.670; 95Â % CI: 1.095â6.510, PÂ =Â 0.031), and emphysema in high-resolution computed tomography (HRCT) (OR: 2.387; 95Â % CI: 1.017â5.640, PÂ =Â 0.046) were independent predictors of progression in F-ILD patients. Conclusions: This study suggested that in patients with F-ILD, long course of disease, elevated blood lymphocyte and emphysema on HRCT were independent predictors of progression, which may suggest utility in early therapeutic intervention
SACE and IL-2R as serum biomarkers for evaluation of multi-organ involvement and prognosis of sarcoidosis
Abstract Background Serum biomarkers in the evaluation of organ involvement and prognostic monitoring of sarcoidosis have not been determined. The purpose of this study was to identify common biomarkers that could be used to assess organ involvement and monitor outcomes in sarcoidosis patients. Methods From Mar 2013 to Sep 2021, patients with newly diagnosed pulmonary sarcoidosis were enrolled in this study in Shanghai Pulmonary Hospital. The information from medical records was retrospectively collected including diagnosis, organ involvement, laboratory tests and follow up data. Differences of continuous variables between groups were analyzed by unpaired Studentâs t-test. Multivariate logistic regression model was performed to identify potential independent factors associated with multiple organ involvement. Results A total of 832 patients were included in the study. There were 339 (40.7%) patients with single organ pulmonary involvement, while 493 (59.3%) patients had two to seven organs involved. Among the routine serum tests, only the serum angiotensin converting enzyme (SACE) level was an independent factor of multiple organ involvement. Compared to those patients without involvement, SACE levels were higher in patients with extra-thoracic lymph node, skin, or spleen involvement as well as abnormal calcium metabolism. Interleukin-2 receptor (IL-2R) levels were higher in patients with extra-thoracic lymph node, spleen involvement and abnormal calcium metabolism than in those without it. The mean levels of SACE and IL-2R showed upward trends paralleling the increase on number of organs involved. In follow up, SACE and IL-2R levels were both decreased in an improved patient group, while there was no obvious difference was noticed before and after treatment in patients with persistent disease. Conclusion SACE and IL-2R were useful as serum biomarkers in the initial evaluation of organ involvement as well as monitoring prognosis in sarcoidosis
Geometry-aware Similarity Learning on SPD Manifolds for Visual Recognition
ISSN:1051-8215ISSN:1558-220
Preliminary characterizations of a serum biomarker for sarcoidosis by comparative proteomic approach with tandem-mass spectrometry in ethnic Han Chinese patients
<p>Abstract</p> <p>Background</p> <p>The diagnosis of sarcoidosis is still a significant challenge in China because of the need to exclude other diseases including granulomatous infections and malignancies that may be clinically and radiographically similar. The specific aim of the study is to search for serum protein biomarkers of sarcoidosis and to validate their clinical usefulness in differential diagnosis.</p> <p>Methods</p> <p>Serum samples were collected from patients with sarcoidosis (nâ=â37), and compared to those from patients with tuberculosis (nâ=â20), other pulmonary diseases (nâ=â20), and healthy volunteers (nâ=â20) for determination of sarcoidosis-specific or -associated protein expression profiles. The first part of this study focused on proteomic analysis of serum from patients with sarcoidosis to identify a pattern of peptides capable of differentiating the studied populations using the ClinProt profiling technology based on mass spectrometry. Enzyme Linked Immunosorbent Assay (ELISA) was then used to verify corresponding elevation of the serum protein concentration of the potential biomarkers in the same patients sets. Receiver operating characteristic curve (ROC) analyses was performed to determine the optimal cutoff value for diagnosis. Immunohistochemistry was carried out to further confirm the protein expression patterns of the biomarkers in lung tissue.</p> <p>Results</p> <p>An unique protein peak of M/Z 3,210 Daltons (Da) was found to be differentially expressed between the sarcoidosis and control groups and was identified as the N-terminal peptide of 29 amino acids (94-122) of serum amyloid A (SAA). ELISA confirmed that the serum SAA level was significantly higher in the sarcoidosis group than that of the other 3 control groups (<it>p</it>â<â0.05). The cutoff for serum SAA concentration determined by ROC analysis was 101.98 ng/ml, with the sensitivity and specificity of 96.3% and 52.5%, respectively. Immunohistochemical staining showed that the SAA depositions in lung tissue of the sarcoidosis patients were also significantly more intense than in non-sarcoid lung tissue (<it>p</it>â<â0.05).</p> <p>Conclusion</p> <p>This is the first study to investigate serum protein markers in Chinese subjects with sarcoidosis. This study shows that the serum SAA expression profiles were different between the sarcoidosis and non-sarcoidosis groups. SAA may be a potential serum biomarker for ruling-out the diagnosis of sarcoidosis in Chinese subjects.</p
Neutron activation analysis and Mössbauer spectroscopy research on coloring mechanism of ancient Chinese Guan porcelain
Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
Abstract Resistance to tamoxifen is a clinically major challenge in breast cancer treatment. Although downregulation of estrogen receptorâalpha (ERα) is the dominant mechanism of tamoxifen resistance, the reason for ERα decrease during tamoxifen therapy remains elusive. Herein, we reported that Spaltâlike transcription factor 2 (SALL2) expression was significantly reduced during tamoxifen therapy through transcription profiling analysis of 9 paired primary preâtamoxifenâtreated and relapsed tamoxifenâresistant breast cancer tissues. SALL2 transcriptionally upregulated ESR1 and PTEN through directly binding to the DNA promoters. By contrast, silencing SALL2 induced downregulation of ERα and PTEN and activated the Akt/mTOR signaling, resulting in estrogenâindependent growth and tamoxifen resistance in ERαâpositive breast cancer. Furthermore, hypermethylation of SALL2 promoter was found in tamoxifenâresistant breast cancer. Importantly, in vivo experiments showed that DNA methyltransferase inhibitorâmediated SALL2 restoration resensitized tamoxifenâresistant breast cancer to tamoxifen therapy. These findings shed light on the mechanism of SALL2 in regulation of ER and represent a potential clinical signature that can be used to categorize breast cancer patients who may benefit from coâtherapy with tamoxifen and DNMT inhibitor